2017 American Transplant Congress
Pre-Transplant CMV-Specific T-Cell Immunity Is an Additional Independent Variable Predicting CMV Infection After Kidney Transplantation.
Background: Current pre-transplant risk stratification for Cytomegalovirus (CMV) infection is based on donor/recipient (D/R) IgG-serostatus and clinical variables such as the use of T-cell depletion…2017 American Transplant Congress
CMV Infection in Renal Transplant Recipients: Incidence and Efficacy of Prophylaxis According to Cytokine Single Nucleotide Polymorphisms.
Nephrology, Hospital Clínico San Carlos, Madrid, Spain
Objectives: To evaluate the influence of single nucleotide polymorphisms (SNP)of IL10, TNFα, IFNγand IL18 in the incidence of CMV infection in renal transplant recipients. Methods:…2017 American Transplant Congress
Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy.
Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection (TCMR) can increase the risk of CMV infection. We purposed to evaluate the effect of valacyclovir…2017 American Transplant Congress
Efficacy and Safety of ASP0113 versus Placebo in CMV-Seronegative Kidney Transplant Patients Receiving an Organ from a CMV-Seropositive Donor.
Introduction: ASP0113 is a first-in-class DNA-based vaccine in development for the prevention of human cytomegalovirus (CMV) infection in at-risk hematopoietic cell transplant and solid organ…2017 American Transplant Congress
Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience.
1Infectious Diseases, Yale University, New Haven, CT; 2Pharmacy, YNHH, New Haven, CT
IntroductionCurrent guidelines on cytomegalovirus (CMV) prophylaxis following organ transplant recommend using valganciclovir (VGCV) 900 mg daily for high (CMV D+/R-) and intermediate (CMV R+) risk…2017 American Transplant Congress
CMV-Specific CD4+ T Cells in CMV-IgG-Seronegative Individuals Protect from CMV Viremia Following Transplantation with a CMV-Seropositive Donor Kidney.
Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, Netherlands
A primary infection with cytomegalovirus (CMV) is one of the major threats following transplantation of a CMV-IgG-seropositive donor organ into a CMV-IgG-seronegative individual. Therefore, prophylactic…2017 American Transplant Congress
Impact of T-Cell Depletion on CMV-Specific Memory T and B Cell Homeostatic Proliferation After Kidney Transplantation.
Human CMV infection is the most common opportunistic infection after kidney transplantation, with a negative impact on kidney allograft outcome. Transplant recipients are at higher…2017 American Transplant Congress
Kinetics of Cytomegalovirus (CMV) DNAemia in CMV Mismatch Solid Organ Transplant Patients with Primary CMV Infection.
Medicine, University of Alberta, Edmonton, Canada
Despite antiviral prophylaxis, CMV infection is common in CMV mismatch (D+/R-) patients. We aimed to study the kinetics of CMV viral load in primary CMV…2017 American Transplant Congress
Donor Macrophage Depletion from CMV-Latently Infected Hearts Abrogates CMV-Accelerated Chronic Rejection.
1Department of Surgery, OHSU, Portland, OR; 2VGTI, OHSU, Hillsboro, OR
Purpose: Latent donor CMV infection has been shown to accelerate chronic rejection (CR) in a heterotopic rat heart transplant model. CMV latency is associated with…2017 American Transplant Congress
Can Viral Load Be Used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Metaanalysis.
Background: Regulatory trials assessing CMV drugs have utilized symptomatic CMV disease as the primary endpoint. However CMV disease occurs infrequently, CMV syndrome is nonspecific, and…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 33
- Next Page »